In this study, 22 inoperable or metastatic NSCLC patients without EGFR/ALK/ROS1 mutations were given sintilimab plus anlotinib until disease progression or unacceptable toxicity [61]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.